Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Short-term Investments (2019 - 2025)

Sunshine Biopharma's Short-term Investments history spans 5 years, with the latest figure at $70457.0 for Q1 2025.

  • For Q1 2025, Short-term Investments changed N/A year-over-year to $70457.0; the TTM value through Mar 2025 reached $70457.0, changed N/A, while the annual FY2021 figure was $7590.0, 0.0% changed from the prior year.
  • Short-term Investments reached $70457.0 in Q1 2025 per SBFM's latest filing, up from $7590.0 in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $70457.0 in Q1 2025 to a low of $7590.0 in Q1 2021.
  • Average Short-term Investments over 3 years is $15448.4, with a median of $7590.0 recorded in 2021.
  • The largest YoY upside for Short-term Investments was 0.0% in 2021 against a maximum downside of 0.0% in 2021.
  • A 3-year view of Short-term Investments shows it stood at $7590.0 in 2021, then changed by 0.0% to $7590.0 in 2022, then soared by 828.29% to $70457.0 in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Short-term Investments are $70457.0 (Q1 2025), $7590.0 (Q3 2022), and $7590.0 (Q2 2022).